We advised Smith+Nephew on the offering

Davis Polk advised Smith+Nephew in connection with its SEC-registered shelf takedown of $700 million aggregate principal amount of 5.750% senior notes due 2036. Davis Polk also advised Smith+Nephew in connection with its concurrent cash tender offer for $250 million aggregate principal amount of its outstanding 2.032% senior notes due 2030.

Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. The company exists to restore people’s bodies and their self-belief by using technology to take the limits off living. Smith+Nephew’s 17,000 employees deliver this mission every day, making a difference in patients’ lives through the excellence of its product portfolio, and the invention and application of new technologies across its three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Founded in Hull, United Kingdom, in 1856, Smith+Nephew now operates in more than 100 countries and generated annual sales of $6.2 billion in 2025.

The Davis Polk corporate team included partner Connie I. Milonakis and associates Gianna Ceophas and Annie Dulka. Counsel John Taylor and associate Mary Valtas provided English law advice. Partner Dominic Foulkes, counsel Alon Gurfinkel and associates Patrick O’Donovan and Ya Sheng Lin provided tax advice. Counsel Sarah E. Kim provided 1940 Act advice. Members of the Davis Polk team are based in the London and New York offices.

Copy link to share post